<DOC>
	<DOC>NCT00174720</DOC>
	<brief_summary>To investigate the efficacy of ciclesonide MDI either as once daily or twice daily in patients with mild to moderate asthma, who have not previously been treated with an inhaled corticosteroid.</brief_summary>
	<brief_title>Efficacy of Ciclesonide vs Placebo Administered as Once Daily or Twice Daily in Patients Not Treated With Inhaled Corticosteroid.</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Ciclesonide</mesh_term>
	<criteria>Males or females 12 years or older History of persistent bronchial asthma for at least 6 months Documented use of bronchodilators (short acting only) only or methylxanthines for at least 1 month before screening At screening, FEV1 60 to 90% of predicted. Reversibility of FEV1 by at least 12% postbronchodilator Be able to use oral inhalers Nonsmokers History of lifethreatening asthma Other pulmonary diseases URI within 4 weeks before screening Use of systemic steroids within 6 months before screening. Use of inhaled steroids within 30 days before screening. More than 2 inpatient hospitalizations or ER visits due to asthma exacerbations in the prior year before screening Pregnant or breastfeeding females Females of childbearing potential not using adequate means of birth control Clinically relevant cardiovascular, hepatic, neurologic, endocrine, or other major systemic disease Abnormal clinical laboratory parameters that would limit participation in the study or interfere with interpretation of study results History of drug or alcohol abuse Treatment with any investigational product within 30 days prior to study entry</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Glucocorticosteroid. Bronchospasm</keyword>
</DOC>